Title

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Authors

Anthony R Mato
Lindsey E Roeker
John N Allan
John M Pagel, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA.Follow
Danielle M Brander
Brian T Hill
Bruce D Cheson
Richard R Furman
Nicole Lamanna
Constantine S Tam
Sasanka Handunnetti
Ryan Jacobs
Frederick Lansigan
Erica Bhavsar
Paul M Barr
Mazyar Shadman
Alan P Skarbnik
Andre Goy
Douglas F Beach
Jakub Svoboda
Jeffrey J Pu
Alison R Sehgal
Clive S Zent
Hande H Tuncer
Stephen J Schuster
Peter V Pickens
Nirav N Shah
Joanna Rhodes
Chaitra S Ujjani
Chadi Nabhan

Document Type

Article

Publication Date

8-21-2018

Publication Title

American journal of hematology

Abstract

Ibrutinib demonstrated superior response rates and survival for treatment-naïve chronic lymphocytic leukemia (CLL) patients in a pivotal study that excluded patients younger than 65 (

Clinical Institute

Cancer

Department

Oncology

Department

Hematology

Recommended Citation

Mato, Anthony R; Roeker, Lindsey E; Allan, John N; Pagel, John M; Brander, Danielle M; Hill, Brian T; Cheson, Bruce D; Furman, Richard R; Lamanna, Nicole; Tam, Constantine S; Handunnetti, Sasanka; Jacobs, Ryan; Lansigan, Frederick; Bhavsar, Erica; Barr, Paul M; Shadman, Mazyar; Skarbnik, Alan P; Goy, Andre; Beach, Douglas F; Svoboda, Jakub; Pu, Jeffrey J; Sehgal, Alison R; Zent, Clive S; Tuncer, Hande H; Schuster, Stephen J; Pickens, Peter V; Shah, Nirav N; Rhodes, Joanna; Ujjani, Chaitra S; and Nabhan, Chadi, "Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial." (2018). Articles, Abstracts, and Reports. 588.
https://digitalcommons.providence.org/publications/588